Kidney Transplant Recipient
16
1
1
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.3%
1 terminated out of 16 trials
90.0%
+3.4% vs benchmark
13%
2 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 9 completed trials
Clinical Trials (16)
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial
Risk Factors Associated With the Absence of CMV-specific Cellular Immune Response in the Early Post-transplant Period in Low-risk CMV-seropositive Kidney Transplant Recipients
Vascular Complications After Kidney Transplantation
Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission
Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
Outcomes of a Pre-operative Exercise Programme for Live Donor and Recipient Kidney Transplant Patients
Subcutaneous Abatacept in Renal Transplant Recipients
Investigation of the Effects of Quadratus Lumborum Block Applied to Patients in Kidney Transplant Surgery
Televideo Exercise and Nutrition Program for Kidney Transplant Recipients
Clinical Significance of 64-slice Multidetector Coronary CT Angiography to Evaluate the Prevalence and Severity of Coronary Artery Disease in Renal Transplant Recipients
Pharmacokinetics of Mmf and Valganciclovir
Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
Isoniazid (INH) Treatment Based on ELISPOT Assay
Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern in Kidney Transplant Recipients